Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kim, Moon J ^a   Park, Quehn ^b   Min, Hyuk K ^c   Kim, Hyun O ^a  

^a Yonsei University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Korean Red Cross   (South Korea)

Author keywords

Blood safety; Donor screening test; Residual risk; Transfusion transmitted infection

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD SAFETY; DONOR SELECTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KOREA; NUCLEIC ACID AMPLIFICATION; RISK ASSESSMENT; SCREENING TEST; VIRUS TRANSMISSION;

BLOOD DONORS; BLOOD TRANSFUSION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; REPUBLIC OF KOREA; RISK ASSESSMENT;

EID: 84868338051     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-160     Document Type: Article

References (30)

1. Kim MJ, Park Q, Seo DH, Lee KN. Residual risk of transfusion-transmitted virus infection among blood donors. Korean J Blood Transfus 2006, 17(Suppl):117.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334(26):1685-1690. 10.1056/NEJM199606273342601, 8637512.
3. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995, 35(2):91-97. 10.1046/j.1537-2995.1995.35295125745.x, 7825218.
4. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV, Barbosa LH, Nemo GJ. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993, 307(6912):1095-1097. 10.1136/bmj.307.6912.1095, 1679121, 8251805.
5. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox sanguinis 2006, 91(1):1-12. 10.1111/j.1423-0410.2006.00773.x, 16856267.
6. Courouce AM, Pillonel J. Estimation of risk of virus transmission in hepatitis B and C and human retrovirus via transfusion of labile blood derivatives. Transfus Clinique et Biologique : J de la Societe Francaise de Transfusion Sanguine 1996, 3(1):13-18.
7. Dodd RY. Notari EPt, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42(8):975-979. 10.1046/j.1537-2995.2002.00174.x, 12385406.
8. Lelie PN, Cuypers HT, Reesink HW, van der Poel CL, Winkel I, Bakker E, van Exel-Oehlers PJ, Vallari D, Allain JP, Mimms L. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol 1992, 37(3):203-209. 10.1002/jmv.1890370310, 1331309.
9. Kim M, Park Q. The hepatitis B virus surface antigen prevalence among Korean blood donors. Korean J Blood Transfus 2011, 22:189-197.
10. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009, 49(8):1609-1620. 10.1111/j.1537-2995.2009.02195.x, 19413732.
11. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002, 42(5):537-548. 10.1046/j.1537-2995.2002.00099.x, 12084161.
12. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002, 42(10):1365-1372. 10.1046/j.1537-2995.2002.00204.x, 12423522.
13. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002, 42(8):980-988. 10.1046/j.1537-2995.2002.00155.x, 12385407.
14. Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002, 42(8):994-998. 10.1046/j.1537-2995.2002.00154.x, 12385409.
15. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47(2):316-325. 10.1111/j.1537-2995.2007.01108.x, 17302779.
16. Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Brunet S, Thierry D, Desenclos JC. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 2008, 48(8):1567-1575. 10.1111/j.1537-2995.2008.01739.x, 18482193.
17. Zuckerman A. Hepatitis Viruses. Medical Microbiology 1996, 849-863. Galveston: The University of Texas Branch at Galveston, Baron S, 4.
18. Brant LJ, Reynolds C, Byrne L, Davison KL. Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008. Transfusion 2011, 51(7):1493-1502. 10.1111/j.1537-2995.2011.03108.x, 21470235.
19. Maresch C, Schluter PJ, Wilson AD, Sleigh A. Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil. Transfusion 2008, 48(2):273-281.
20. Otsubo H, Yamaguchi K. Current risks in blood transfusion in Japan. Jpn J Infect Dis 2008, 61(6):427-433.
21. Oh HB, Whang GK, Kim SI. Seroincidence of hepatitis B virus among Korean blood donors. Korean Soc Blood Transfus 1999, 10(1):1-4.
22. Gonzalez R, Echevarria JM, Avellon A, Barea L, Castro E. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion 2006, 46(7):1138-1142. 10.1111/j.1537-2995.2006.00863.x, 16836560.
23. Sabino EC, Goncalez TT, Carneiro-Proietti AB, Sarr M, Ferreira JE, Sampaio DA, Salles NA, Wright DJ, Custer B, Busch M. Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus Epidemiology Donor Study-II blood centers in Brazil. Transfusion 2011, 52(4):870-879.
24. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993, 341(8859):1501-1504. 10.1016/0140-6736(93)90635-T, 8099380.
25. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000, 284(2):210-214. 10.1001/jama.284.2.210, 10889595.
26. Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995, 2(3):121-132. 10.1111/j.1365-2893.1995.tb00017.x, 7493306.
27. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, Group N-RNS. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005, 45(2):254-264. 10.1111/j.1537-2995.2004.04215.x, 15660836.
28. Hepatitis B. Countries or areas at risk http://gamapserver.who.int/mapLibrary/Files/Maps/Global_HepB_ITHRiskMap.png.
29. Statistic KH. Kora National Health and Nutrition Examination Survey (KNHANES V-1) 2010, 2011. In: Ministry of Health and Welfare, Korea Center for Disease Control and Prevention.
30. Kim H, Hur M, Moon HW, Park CM, Cho JH, Park KS, Lee K, Chang S. Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity. Ann Lab Med 2012, 32(1):73-78. 10.3343/alm.2012.32.1.73, 3255487, 22259782.